CEO Executive AssistantA major medical device product launch is one of the most complex and time-intensive events in a device company CEO’s calendar. Cross-functional coordination between regulatory, clinical, commercial, marketing, supply chain, and medical affairs functions reaches its peak intensity. Key opinion leader engagement, payer relations, health system partnership discussions, and FDA post-clearance obligations all require executive-level attention simultaneously. And the competitive environment does not pause while you are consumed with launch activities.
Medical device CEOs who navigate product launches most effectively are those who have resolved the fundamental tension in advance: the launch requires enormous organizational energy and coordination, but it should not require disproportionate CEO time at the operational level. The CEO’s role in a product launch is strategic and relational, not operational. Building the organizational structure and pre-launch preparation that allows this division of labor is the foundational time management investment.
FDA guidance on medical device commercial practices and industry research consistently show that regulatory compliance during commercial launch is one of the highest-risk periods for device companies. CEO time investment in ensuring compliant commercial practices is genuinely warranted during this phase.
The Pre-Launch Time Investment That Saves Launch-Phase Time
The most effective time management strategy for a medical device product launch is front-loading CEO involvement in the pre-launch planning phase to minimize CEO involvement in launch-phase execution. This means investing significant personal time in the three to six months before launch to ensure that: the commercial strategy is clear and aligned across functions, the launch team is structured with appropriate leadership and authority, the key decision criteria for major launch-phase decisions are established in advance, and the CEO’s personal engagement calendar is planned and communicated.
When this pre-launch investment is made, the CEO arrives at launch with a team that knows the strategy, the authority to execute it, and clarity about when and why to escalate. Launch-phase surprises require CEO attention. A well-planned launch has fewer surprises because the planning process identified risks and prepared contingencies in advance.
The CEO’s Launch-Phase Engagement Calendar
For the launch period (typically the first six months of commercial availability), the CEO’s engagement calendar should reflect a specific allocation across the categories of work that genuinely require CEO-level involvement.
Key opinion leader and clinical champion engagement. In medical device markets, early clinical adopters and key opinion leaders have outsized influence on adoption rates and clinical acceptance. The CEO’s presence in relationships with these individuals signals commitment and provides a level of partnership that competitors with less engaged leadership cannot match. Schedule regular touchpoints with your top 10 to 15 clinical champions, whether through advisory board meetings, site visits, or individual calls.
Major health system partnership development. Device adoption at scale often depends on system-level agreements with major health systems. These negotiations require CEO-level relationship management and decision-making authority. Protect time for these conversations and ensure that your commercial leadership team brings you in at the right moment in negotiations: when the relationship has been established and when a CEO-to-CEO or CEO-to-CMO conversation adds genuine value.
Investor and analyst communication. Product launches are significant investor events that require regular, confident CEO communication. Your investor relations and launch communication should be planned in advance with specific milestone-based messaging, so that CEO communications are coordinated and strategic rather than reactive and improvised.
Regulatory compliance monitoring. Post-clearance compliance obligations during commercial launch (MDR reporting, complaint handling, promotional material review) require CEO awareness and board-level accountability. Regular structured briefings from your regulatory and quality leadership, rather than operational involvement in compliance processes, keeps you appropriately informed without drawing you into process execution.
Delegation Architecture for Launch Execution
The launch execution functions that should be fully delegated include: day-to-day commercial field management (owned by the VP of Sales or Chief Commercial Officer), marketing campaign execution and materials development (owned by Marketing), clinical support and training program management (owned by Clinical Affairs), supply chain management and inventory allocation (owned by Operations), and customer complaint and adverse event management within the complaint handling procedure (owned by Quality).
Each of these functional leaders should have clear authority within their domain and a clear escalation path for decisions that exceed their authority. A weekly launch team meeting that brings these functional leaders together to surface cross-functional issues is appropriate for ensuring coordination. The CEO does not need to be in this meeting every week; a biweekly or monthly attendance with the team’s regular report providing interim updates may be sufficient.
See delegation for hospital CEOs, which covers the authority framework principles that apply equally to the medical device launch context. The same principles of clear authority, genuine accountability, and structured oversight govern effective delegation during a high-stakes commercial event.
Managing Time in High-Demand Commercial Regions
Product launches often have geographic concentration: a few regions or institutions where the launch is progressing fastest, attracting the most attention, and generating the most learning. These regions create pull for CEO time and attention that needs to be managed carefully.
A practical approach is to schedule one or two high-value regional engagements per month that are planned in advance rather than reactive. These engagements should be concentrated in regions where CEO presence adds the most strategic value: the largest potential accounts, the most influential opinion leaders, the most important partnership conversations. They should not be determined by which region is experiencing the most difficulty, which is an operational issue for the commercial leadership team to address.
The calendar management for hospital CEOs framework for structuring external engagement applies directly to the medical device commercial context: CEO presence is a finite and valuable resource that should be allocated to maximize strategic impact rather than distributed reactively.
Protecting Strategy Beyond the Launch
One of the most common time management failures during a product launch is the temporary suspension of all forward-looking strategic work. When the launch consumes CEO attention completely, the pipeline development work, business development conversations, and organizational capability investments that will determine the company’s performance in two to five years all stall.
The paradox is that the launch creates exactly the moment when future strategy needs attention. Launch performance data is revealing what the market values, what clinical users need, and where competitive gaps exist. Investor relationships established during the launch create future financing opportunities. Key opinion leader relationships developed during the launch can inform next-generation product development. These opportunities require strategic attention to capture.
Protect at minimum one morning per week for forward-looking strategic work during the launch period. Use it for pipeline strategy, business development relationship development, and the pattern recognition from launch data that will inform future product and market decisions. The launch is not the endpoint of the company’s strategy. It is the beginning of the commercial phase, and the CEO who maintains strategic perspective throughout the launch will position the company better for what comes next.
Maintaining Personal Performance During a Launch
Product launches, like mergers and regulatory processes, are high-intensity periods that create genuine physical and cognitive demand. The temptation to sacrifice sleep, exercise, and personal recovery for launch-related work is strong and counterproductive.
Launches are typically six-to-twelve-month events. The CEO who arrives at month three in a state of depletion will manage the critical commercial ramp period less effectively than one who maintained baseline recovery practices throughout. Building non-negotiable recovery commitments (adequate sleep, consistent physical activity, planned personal time) into the launch period schedule from the beginning is not a concession to personal need. It is a professional investment in the quality of leadership the launch requires.
Medical device product launches test every dimension of a CEO’s leadership capability. The executives who perform best in this environment are those who entered it with a clear understanding of their specific role, a well-designed organizational structure for execution, and the personal discipline to maintain their own performance through a sustained period of elevated demand.
Related Reading
For further context, explore How Medical Device CEOs Manage Time Around Critical Regulatory Submissions and Adapting the Pomodoro Technique for the Demands of a Healthcare Executive.